FI974321A0 - Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa - Google Patents

Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa

Info

Publication number
FI974321A0
FI974321A0 FI974321A FI974321A FI974321A0 FI 974321 A0 FI974321 A0 FI 974321A0 FI 974321 A FI974321 A FI 974321A FI 974321 A FI974321 A FI 974321A FI 974321 A0 FI974321 A0 FI 974321A0
Authority
FI
Finland
Prior art keywords
heparin
glycosaminoglycans
compounds
present
molecules
Prior art date
Application number
FI974321A
Other languages
English (en)
Inventor
Riitta Lassila
Petri Kovanen
Ken Lindstedt
Original Assignee
Jenny Ja Antti Wihurin Rahasto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenny Ja Antti Wihurin Rahasto filed Critical Jenny Ja Antti Wihurin Rahasto
Priority to FI974321A priority Critical patent/FI974321A0/fi
Publication of FI974321A0 publication Critical patent/FI974321A0/fi
Priority to DK98955631T priority patent/DK1034189T3/da
Priority to EP07118457A priority patent/EP1916260A1/en
Priority to ES98955631T priority patent/ES2296346T3/es
Priority to DE69838732T priority patent/DE69838732T2/de
Priority to EP98955631A priority patent/EP1034189B1/en
Priority to JP2000522138A priority patent/JP2001524555A/ja
Priority to AU12401/99A priority patent/AU764410B2/en
Priority to US09/230,097 priority patent/US20020016308A1/en
Priority to PCT/FI1998/000925 priority patent/WO1999026983A1/en
Priority to AT98955631T priority patent/ATE378358T1/de
Priority to CA2311670A priority patent/CA2311670C/en
Priority to US10/418,095 priority patent/US7314860B2/en
Priority to US11/826,668 priority patent/US7504113B2/en
Priority to US12/371,195 priority patent/US8415324B2/en
Priority to JP2010167172A priority patent/JP2011017003A/ja
Priority to JP2011000047A priority patent/JP2011121956A/ja
Priority to JP2011000046A priority patent/JP2011121955A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0081—Reaction with amino acids, peptides, or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0066—Isolation or extraction of proteoglycans from organs
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
FI974321A 1997-11-25 1997-11-25 Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa FI974321A0 (fi)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FI974321A FI974321A0 (fi) 1997-11-25 1997-11-25 Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
CA2311670A CA2311670C (en) 1997-11-25 1998-11-25 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
US09/230,097 US20020016308A1 (en) 1997-11-25 1998-11-25 Heparin-like compounds, their preparation and use to prevent arterial thrombsis associated with vascular injury and intervetions
AT98955631T ATE378358T1 (de) 1997-11-25 1998-11-25 Heparinähnliche verbindungen, ihre herstellung und verwendung zur verhinderung arterieller thrombose, verbunden mit vaskulärer verletzung und eingriffen
ES98955631T ES2296346T3 (es) 1997-11-25 1998-11-25 Compuestos similares a la heparina, su preparacion y utilizacion para prevenir la trombosis arterial asociada a lesiones e intervenciones vasculares.
DE69838732T DE69838732T2 (de) 1997-11-25 1998-11-25 Heparinähnliche verbindungen, ihre herstellung und verwendung zur verhinderung arterieller thrombose, verbunden mit vaskulärer verletzung und eingriffen
EP98955631A EP1034189B1 (en) 1997-11-25 1998-11-25 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
JP2000522138A JP2001524555A (ja) 1997-11-25 1998-11-25 ヘパリン様化合物、その製造並びに血管傷害および介入による動脈血栓を阻害するための使用
AU12401/99A AU764410B2 (en) 1997-11-25 1998-11-25 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
DK98955631T DK1034189T3 (da) 1997-11-25 1998-11-25 Heparinlignende forbindelser, fremstilling og anvendelse deraf til forebyggelse af arteriel thrombose associeret med vaskulære beskadigelser og interventioner
PCT/FI1998/000925 WO1999026983A1 (en) 1997-11-25 1998-11-25 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
EP07118457A EP1916260A1 (en) 1997-11-25 1998-11-25 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
US10/418,095 US7314860B2 (en) 1997-11-25 2003-04-18 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
US11/826,668 US7504113B2 (en) 1997-11-25 2007-07-17 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
US12/371,195 US8415324B2 (en) 1997-11-25 2009-02-13 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
JP2010167172A JP2011017003A (ja) 1997-11-25 2010-07-26 ヘパリン様化合物、その製造並びに血管傷害および介入による動脈血栓を阻害するための使用
JP2011000047A JP2011121956A (ja) 1997-11-25 2011-01-04 ヘパリン様化合物、その製造並びに血管傷害および介入に伴う動脈血栓を阻止するための使用
JP2011000046A JP2011121955A (ja) 1997-11-25 2011-01-04 ヘパリン様化合物、その製造並びに血管傷害および介入に伴う動脈血栓を阻止するための使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI974321A FI974321A0 (fi) 1997-11-25 1997-11-25 Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa

Publications (1)

Publication Number Publication Date
FI974321A0 true FI974321A0 (fi) 1997-11-25

Family

ID=8550007

Family Applications (1)

Application Number Title Priority Date Filing Date
FI974321A FI974321A0 (fi) 1997-11-25 1997-11-25 Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa

Country Status (11)

Country Link
US (4) US20020016308A1 (fi)
EP (2) EP1034189B1 (fi)
JP (4) JP2001524555A (fi)
AT (1) ATE378358T1 (fi)
AU (1) AU764410B2 (fi)
CA (1) CA2311670C (fi)
DE (1) DE69838732T2 (fi)
DK (1) DK1034189T3 (fi)
ES (1) ES2296346T3 (fi)
FI (1) FI974321A0 (fi)
WO (1) WO1999026983A1 (fi)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
SE0000363L (sv) * 2000-02-04 2001-08-05 Zoucas Kirurgkonsult Ab Belagd medicinsk anordning
SE523216C2 (sv) * 2001-07-27 2004-04-06 Zoucas Kirurgkonsult Ab Heparinstent
FR2831186B1 (fr) * 2001-10-22 2004-06-18 Aventis Pharma Sa Production d'heparine a partir de cultures de mastocytes
DE10221055B4 (de) * 2002-05-10 2007-10-25 Hemoteq Ag Verbindungen zur hämokompatiblen Beschichtung von Oberflächen, Verfahren zu deren Herstellung und deren Verwendung
NZ536330A (en) * 2002-05-09 2007-08-31 Hemoteq Ag Medical devices such as stents comprising haemocompatible coating, production and use thereof
FR2853663B1 (fr) * 2003-04-14 2007-08-31 Aventis Pharma Sa Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
US9114194B2 (en) 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8496953B2 (en) 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
US8986713B2 (en) 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
DE102008032361A1 (de) 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
ES2682482T3 (es) 2011-03-11 2018-09-20 W. L. Gore & Associates, Inc. Mejoras para las entidades biológicas inmovilizadas
PL3821897T3 (pl) * 2011-12-22 2022-11-21 Corline Biomedical Ab Środek i sposób leczenia naczyń krwionośnych
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
US20150305892A1 (en) * 2014-04-25 2015-10-29 Abbott Cardiovascular Systems Inc. Methods and Devices for Treating a Bodily Lumen with In Situ Generated Structural Support
GB201415062D0 (en) 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
KR102415502B1 (ko) * 2015-08-07 2022-07-01 삼성전자주식회사 복수의 사용자를 위한 라이트 필드 렌더링 방법 및 장치
CA3035659C (en) * 2016-09-16 2022-09-06 Glycologix, Llc Sulfated glycosaminoglycan biomaterials as proteoglycan mimics

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265827A (en) * 1971-03-08 1981-05-05 Monsanto Company Catalytic asymmetric hydrogenation
SE425372B (sv) * 1977-07-18 1982-09-27 Ird Biomaterial Ab Sett att heparinisera en elektriskt laddad yta pa en medecinsk artikel avsedd att komma i kontakt med blod och medel for utforande av settet
US4350629A (en) * 1981-07-29 1982-09-21 Massachusetts Institute Of Technology Procedures for preparing composite materials from collagen and glycosaminoglycan
NL188622C (nl) 1981-12-15 1992-08-17 Cordis Europ Werkwijze ter verbetering van de bloedcompatibiliteit van een materiaaloppervlak door bekleding daarvan met een heparine of heparine-analoga en een eiwit houdende film, alsmede voorwerp, omvattende een oppervlak met verbeterde bloedcompatibiliteit verkregen onder toepassing van een op het oppervlak aangebrachte heparine of heparine-analoga en een eiwit houdende film.
US4863907A (en) * 1984-06-29 1989-09-05 Seikagaku Kogyo Co., Ltd. Crosslinked glycosaminoglycans and their use
DE3639561A1 (de) * 1986-11-20 1988-06-01 Baumann Hanno Verfahren zur herstellung von nicht-thrombogenen substraten
DK505488D0 (da) 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5019393A (en) * 1988-08-03 1991-05-28 New England Deaconess Hospital Corporation Biocompatible substance with thromboresistance
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
WO1991015252A1 (en) 1990-04-10 1991-10-17 Chembiomed, Ltd. Nonthrombogenic glycosaminoglycan copolymers
FR2661332B1 (fr) 1990-04-25 1995-06-16 Michel Jean Pierre Prothese ligamentaire et son procede de fabrication.
IT1251183B (it) * 1991-08-28 1995-05-04 Opocrin Spa Dermatan solfato ad alto titolo, dotato di elevata attivita' trombolitica, e forme farmaceutiche che lo contengono.
SE470006B (sv) * 1991-09-26 1993-10-25 Corline Systems Ab Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
AU2865692A (en) * 1991-10-04 1993-05-03 Virginia Commonwealth University Von willebrand factor-specific heparin fractions
US5571166A (en) * 1992-03-19 1996-11-05 Medtronic, Inc. Method of making an intraluminal stent
WO1994029436A1 (en) * 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
US5618298A (en) * 1993-10-23 1997-04-08 Simon; Michael Vascular prosthesis made of resorbable material
US7229755B1 (en) * 1993-11-17 2007-06-12 Dana Farber Cancer Institute, Inc. Method for detection of alterations in the DNA mismatch repair pathway
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
AU700584C (en) * 1994-08-12 2002-03-28 Meadox Medicals, Inc. Vascular graft impregnated with a heparin-containing collagen sealant
US5643580A (en) * 1994-10-17 1997-07-01 Surface Genesis, Inc. Biocompatible coating, medical device using the same and methods
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US5702754A (en) * 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
JPH09169801A (ja) * 1995-10-17 1997-06-30 Terumo Corp ヘパリン複合体およびそれを被覆した医療器具
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5876433A (en) * 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US5865827A (en) * 1997-06-03 1999-02-02 Bullister; Edward T Vacuum device for securing human tissue
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa

Also Published As

Publication number Publication date
US20020016308A1 (en) 2002-02-07
US20090202607A1 (en) 2009-08-13
US20080014239A1 (en) 2008-01-17
JP2001524555A (ja) 2001-12-04
JP2011121955A (ja) 2011-06-23
AU1240199A (en) 1999-06-15
EP1034189B1 (en) 2007-11-14
ES2296346T3 (es) 2008-04-16
EP1916260A1 (en) 2008-04-30
DE69838732D1 (de) 2007-12-27
CA2311670A1 (en) 1999-06-03
WO1999026983A1 (en) 1999-06-03
EP1034189A1 (en) 2000-09-13
JP2011017003A (ja) 2011-01-27
US7314860B2 (en) 2008-01-01
DK1034189T3 (da) 2008-02-25
CA2311670C (en) 2010-02-09
US7504113B2 (en) 2009-03-17
DE69838732T2 (de) 2008-10-30
JP2011121956A (ja) 2011-06-23
AU764410B2 (en) 2003-08-21
US8415324B2 (en) 2013-04-09
ATE378358T1 (de) 2007-11-15
US20030212042A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
FI974321A0 (fi) Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
Laberge et al. Microvesicles: Intercellular messengers in cutaneous wound healing
ES2367121T3 (es) Derivados de exopolisacaridos (eps) despolimerizados sulfatados, su preparación y sus usos.
BR0016336A (pt) Combinações de substâncias ativas fungicidas
Alban et al. Partial synthetic glucan sulfates as potential new antithrombotics: a review
WO2004076637A3 (en) Cell-polymer fiber compositions and use thereof
Hofbauer et al. Hydroxyethyl starch reduces the chemotaxis of white cells through endothelial cell monolayers
Sharma et al. Investigations of the effectiveness of heparin variants as inhibitors of histones
ATE421319T1 (de) Mit s-nitrosothiol angereicherte erythrocyten und deren verwendung
King et al. Hyaluronan in skin wound healing: therapeutic applications
Wu et al. Mesenchymal stem cell-derived exosomes: The dawn of diabetic wound healing
Shirk et al. Arterial smooth muscle cell heparan sulfate proteoglycans accelerate thrombin inhibition by heparin cofactor II
Matalon et al. Interstitial fluid volumes and albumin spaces in pulmonary oxygen toxicity
Kozlowski et al. Structure and biological activities of glycosaminoglycan analogs from marine invertebrates: new therapeutic agents?
Liu Trafficking of hyaluronan in the interstitium and its possible implications
PT1284750E (pt) Composição farmacêutica
Reignier et al. Prevention of ischemia-reperfusion lung injury by sulfated Lewisa pentasaccharide
Pavão Glycans in Diseases and Therapeutics
BR9601989A (pt) Indenoilguanidinas processo para sua preparação seus usos e medicamento
DE69120925T2 (de) Hämoglobin-oligomer basierte komposition und seine herstellung
DE69630639D1 (de) Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs
BR0012573A (pt) Combinações de substâncias ativas fungicidas
Charef et al. Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally
Massry Exosome-Mediated Crosstalk between Keratinocytes and Macrophages in Cutaneous Wound Healing
US11744858B2 (en) Medicine for treatment and/or prevention of ischemic diseases, method for improving angiogenesis-promoting activity of cells, or method for producing medicine

Legal Events

Date Code Title Description
FD Application lapsed